{"id":"W4411351237","doi":"10.1002/hon.70093_76","title":"76 | GLOFITAMAB PLUS GEMCITABINE AND OXALIPLATIN (Glofit‐GemOx) IN PATIENTS WITH RELAPSED/REFRACTORY (R/R) DIFFUSE LARGE B‐CELL LYMPHOMA (DLBCL): 2‐YEAR FOLLOW‐UP OF STARGLO","year":2025,"lang":"en","type":"article","venue":"Hematological Oncology","topic":"Chronic Lymphocytic Leukemia Research","field":"Medicine","cited_by":2,"is_retracted":false,"has_abstract":true,"ca_institutions":"Roche (Canada)","funders":"Genentech; University College London; F. Hoffmann-La Roche; BeiGene; Sanofi","keywords":"Gemcitabine; Oxaliplatin; Diffuse large B-cell lymphoma; Refractory (planetary science); Medicine; Oncology; Lymphoma; Internal medicine; Chemotherapy; Materials science; Cancer; Colorectal cancer; Metallurgy","routes":{"ca_aff":true,"ca_fund":false,"ca_venue":false,"about_ca":false,"invisible_to_affiliation_only":false},"retraction":null,"screen":null,"direct_labels":[],"prediction":{"model_version":"metacan-v3-hybrid-931329e0061c","candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.001594852,0.0003962152,0.001099252,0.0002420045,0.0002397964,0.0008369424,0.0003237515,0.000544419,0.001542452],"category_scores_gemma":[0.0009802987,0.0002756991,0.001477925,0.0004102691,0.0003002927,0.0007232422,0.0003085295,0.001151587,0.0004236256],"about_ca_system_candidate":false,"about_ca_system_consensus":false,"about_ca_system_score_codex":0.000790239,"about_ca_system_score_gemma":0.0006159628,"about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_topic_score_codex":0.0009946992,"about_ca_topic_score_gemma":0.002115205,"domain_scores_codex":[0.9995648,0.0001444924,0.00004165359,0.00010153,0.00005760076,0.00008983397],"domain_scores_gemma":[0.9993242,0.0001096482,0.0002411537,0.00006804446,0.00004265576,0.0002143438],"domain_codex":null,"domain_gemma":null,"domain_candidate":null,"domain_consensus":null,"study_design_codex":"randomized_trial","study_design_gemma":"nonrandomized_trial","study_design_scores_codex":[0.6325511,0.007886731,0.1217736,0.0008955957,0.004791902,0.0003806387,0.0002762455,0.00327709,0.01066078,0.000228475,0.00642861,0.2108492],"study_design_scores_gemma":[0.1571001,0.3416,0.4702811,0.0001947713,0.007534367,0.00111048,0.0002367776,0.003384046,0.004797234,0.0007143654,0.01294179,0.0001049368],"study_design_candidate":"nonrandomized_trial","study_design_consensus":null,"genre_codex":"empirical","genre_gemma":"empirical","genre_scores_codex":[0.9938163,0.002980743,0.0002110309,0.0002221958,0.00005325946,0.0001824174,0.001295967,0.00002977854,0.001208447],"genre_scores_gemma":[0.9949219,0.000862486,0.0002208303,0.0003697876,0.0000560257,0.0001195944,0.00263789,0.000007676549,0.0008038851],"genre_candidate":"empirical","genre_consensus":"empirical","teacher_disagreement_score":0.001594852,"threshold_uncertainty_score":0.008434534,"prediction_status":"machine_predicted_unvalidated"},"machine_scores":{"provisional":true,"baseline":true,"maturity_gate_passed":false,"score_opus":0.01284584267870639,"score_gpt":0.2859185327758965,"score_spread":0.2730726900971901,"validation_status":"score_only:v0-immature-baseline","note":"Baseline scores from an immature model (maturity gate not passed). Scores rank; they never assert a category."}}